Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CNTB | US
0.04
1.44%
Healthcare
Biotechnology
30/06/2024
10/04/2026
2.82
2.80
2.87
2.72
Connect Biopharma Holdings Limited a clinical-stage biopharmaceutical company focuses on developing therapies to treat T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is CBP-201 an antibody to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis (AD) and asthma. The company's product candidates also comprise CBP-307 a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis; and CBP-174 a peripherally acting antagonist of histamine receptor 3 in development for the treatment of pruritus associated with skin inflammation. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego California.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
123.8%1 month
110.6%3 months
93.8%6 months
98.9%-
0.77
0.62
0.00
0.00
0.19
-
-
-24.95M
155.82M
155.82M
-
24.64
-
-
-17.92
1.17
0.12
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.27
Range1M
1.27
Range3M
1.80
Rel. volume
0.55
Price X volume
565.55K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Protalix BioTherapeutics Inc | PLX | Biotechnology | 2.3 | 169.15M | 0.88% | n/a | 91.50% |
| Adagene Inc. | ADAG | Biotechnology | 3.8 | 168.23M | -1.17% | n/a | 36.29% |
| Fennec Pharmaceuticals Inc | FENC | Biotechnology | 5.81 | 163.71M | -9.22% | 64.86 | -2193.44% |
| Immuneering Corporation Class A Common Stock | IMRX | Biotechnology | 5.52 | 163.69M | -2.47% | n/a | 6.50% |
| Codexis Inc | CDXS | Biotechnology | 2.24 | 158.88M | -6.67% | n/a | 69.22% |
| OBIO | OBIO | Biotechnology | 4.13 | 156.22M | -2.36% | n/a | 3.29% |
| Candel Therapeutics Inc. Common Stock | CADL | Biotechnology | 4.83 | 154.97M | 0.62% | n/a | -186.13% |
| BriaCell Therapeutics Corp. Common Shares | BCTX | Biotechnology | 4.28 | 153.60M | -5.73% | n/a | 0.00% |
| Nuvectis Pharma Inc. | NVCT | Biotechnology | 8.22 | 153.33M | 0.74% | n/a | 0.00% |
| Nkarta Inc | NKTX | Biotechnology | 2.17 | 153.11M | -7.26% | n/a | 18.88% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 10.06 | 161.53M | -1.08% | n/a | 286.96% |
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 34.925 | 100.30M | 2.42% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 5.62 | 91.55M | 1.81% | 9.09 | 39.79% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 11.78 | 73.76M | 1.38% | 14.48 | 7.10% |
| ILAG | ILAG | Building Products & Equipment | 3.55 | 64.11M | 0.00% | n/a | 5.48% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 11.76 | 17.91M | 6.72% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.08 | 15.78M | -6.90% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.601 | 11.61M | -7.68% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.34 | 3.42M | 3.08% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.2536 | 2.41M | -15.10% | n/a | 19.98% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.19 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.62 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 93.83 | - | Riskier |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 155.82M | - | Emerging |